MedPath
Found 103 clinical trials|View Analysis
Sort by:

Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer

Phase 2
Not yet recruiting
Conditions
Gastric (Stomach) Cancer
Interventions
Drug: Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib
First Posted Date
2024-12-27
Last Posted Date
2024-12-27
Lead Sponsor
Fudan University
Target Recruit Count
141
Registration Number
NCT06748508
Locations
🇨🇳

Fudan University Cancer Hospital, Shanghai, Shanghai, China

🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children with Palmoplantar Wart

Not Applicable
Not yet recruiting
Conditions
Common Warts
Interventions
First Posted Date
2024-12-17
Last Posted Date
2024-12-17
Lead Sponsor
Mazandaran University of Medical Sciences
Target Recruit Count
60
Registration Number
NCT06737406
Locations
🇮🇷

Iran, Sari, Mazandaran, Iran, Islamic Republic of

Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma

Phase 1
Not yet recruiting
Conditions
Esophagogastric Adenocarcinoma
Interventions
First Posted Date
2024-12-12
Last Posted Date
2024-12-19
Lead Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Target Recruit Count
36
Registration Number
NCT06731803
Locations
🇩🇪

Universitätsklinikum Leipzig, Leipzig, Germany

Combination Therapy of 5-Fluorouracil and CALcipotriol Versus 5-Fluorouracil in the Treatment of Actinic Keratosis

Phase 4
Recruiting
Conditions
Actinic Keratoses
Interventions
Drug: 5FU-Calcipotriol
Drug: 5-FU 50 MG/ML Topical Cream
First Posted Date
2024-07-12
Last Posted Date
2024-10-26
Lead Sponsor
Maastricht University Medical Center
Target Recruit Count
232
Registration Number
NCT06499415
Locations
🇳🇱

Catharina Hospital Eindhoven, Eindhoven, Brabant, Netherlands

🇳🇱

Zuyderland Medical Center, Heerlen, Limburg, Netherlands

🇳🇱

Maastricht University Medical Center, Maastricht, Limburg, Netherlands

and more 1 locations

Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer

Phase 2
Not yet recruiting
Conditions
Gastric Cancer
Interventions
First Posted Date
2023-03-02
Last Posted Date
2023-06-22
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
39
Registration Number
NCT05751265

The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer

Phase 2
Recruiting
Conditions
Recurrent Rectal Cancer
Interventions
First Posted Date
2022-11-28
Last Posted Date
2024-10-01
Lead Sponsor
Fudan University
Target Recruit Count
93
Registration Number
NCT05628038
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Phase 1
Recruiting
Conditions
Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma
Head and Neck Carcinoma
Head and Neck Cancer Stage IV
Head and Neck Cancers - Throat
Interventions
First Posted Date
2022-09-02
Last Posted Date
2024-11-22
Lead Sponsor
University of Chicago
Target Recruit Count
30
Registration Number
NCT05526924
Locations
🇺🇸

The University of Chicago, Chicago, Illinois, United States

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

Phase 1
Withdrawn
Conditions
Pancreatic Cancer
Unresectable Pancreatic Cancer
Metastatic Pancreatic Cancer
KRAS P.G12C
Interventions
Drug: Sotorasib
Drug: Liposomal Irinotecan (nal-IRI)
Drug: 5 Fluorouracil (5FU)
Drug: Leucovorin (LV)
Drug: Gemcitabine (GEM)
Drug: Nab paclitaxel
First Posted Date
2022-02-22
Last Posted Date
2023-05-11
Lead Sponsor
Devalingam Mahalingam
Registration Number
NCT05251038
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer

Phase 2
Conditions
FOLFOXIRI Regimen
High-risk Locally Advanced Colorectal Cancer
Neoadjuvant Chemotherapy
Interventions
First Posted Date
2021-08-24
Last Posted Date
2021-08-24
Lead Sponsor
West China Hospital
Target Recruit Count
69
Registration Number
NCT05018182
Locations
🇨🇳

Sichuan University West China Hospital, Chengdu, Sichuan, China

Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait

Not Applicable
Recruiting
Conditions
Rectal Cancer
Consolidation
Interventions
First Posted Date
2021-08-11
Last Posted Date
2024-11-27
Lead Sponsor
Hospital Alemão Oswaldo Cruz
Target Recruit Count
216
Registration Number
NCT05000697
Locations
🇦🇷

Hospital de Gastroenterologia Udaondo Ciudad de Buenos Aires, Buenos Aires, Argentina

🇦🇷

Hospital Ramos Mejia: Hospital General de Agudos Dr. Jose Maria Ramos Mejia, Buenos Aires, Argentina

🇦🇷

Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

and more 21 locations
© Copyright 2025. All Rights Reserved by MedPath